Resúmenes de Ponencias - Sociedad Española de Oncología Médica

4. Henderson IC, Berry DA, Demetri GD, et al: Improved Outcomes From Adding Sequential Paclitaxel but Not From
Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast
cáncer. J Clin Oncol:JCO.2003.02.063, 2003.
5. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal
women with early breast cáncer: first results of the ATAC randomized trial. Lancet 359:2131-9, 2002.
6. Citron ML, Berry DA, Cirrincione C, et al: Randomized Trial of Dose-Dense Versus Conventionally Scheduled and
Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive
Primary Breast cáncer: First Report of Intergroup Trial C9741/cáncer and Leukemia Group B Trial 9741. J Clin
Oncol:JCO.2003.09.081, 2003.
7. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor
growth. cáncer Cell 2:127-137, 2002.
8. Howe LR, Subbaramaiah K, Patel J, et al: Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human
epidermal growth factor receptor 2 (HER-2)/neu-induced breast cáncer. cáncer Res 62:5405-7, 2002.
9. Gibbs JB: Mechanism-Based Target Identification and Drug Discovery in cáncer Research. Science 287:1969-1973,
2000.
10. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expresión profiling predicts clinical outcome of breast cáncer.
Nature 415:530-536, 2002.
11. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expresión signature as a predictor of survival in breast cáncer.
N Engl J Med 347:1999-2009, 2002.
66
Congreso
IXSEOM